龙头药企，一指尽揽！全市场唯一“药ETF”联接基金”今日火热开售

Group 1 - The article announces the exclusive launch of the only "Pharmaceutical ETF" in the market, which includes leading companies in chemical drugs, biological drugs, and traditional Chinese medicine, starting from August 8 [1][3] - The pharmaceutical industry is characterized by its strong demand attributes, driven by a large population base, accelerated aging, and rising GDP per capita, indicating a long-term high prosperity in the sector [3][4] - By 2024, the proportion of the population aged 65 and above in China is expected to reach 15.6%, marking the entry into a moderately aging society, which will further expand the pharmaceutical market space [4] Group 2 - The innovative drugs are seen as a typical representative of new productive forces, expected to drive the revaluation of medical assets and open up growth ceilings for the pharmaceutical industry [4] - The domestic innovative drug market is predicted to experience significant growth, with the potential for a "Davis Double Hit" in 2024 due to multiple internal and external catalysts [4] - The pharmaceutical index has shown a significantly smaller decline compared to similar indices over the past five years, with positive returns in the last three years [14][15] Group 3 - The pharmaceutical index includes leading listed companies in the three major pharmaceutical sectors: chemical drugs, biological drugs, and traditional Chinese medicine, reflecting the overall performance of pharmaceutical theme stocks [7][11] - The top ten constituent stocks of the pharmaceutical index include major companies such as Heng Rui Pharmaceutical, with a market capitalization of 374.3 billion yuan, and Yunnan Baiyao, with a market capitalization of 100.9 billion yuan [12][13] - The current point of the pharmaceutical index is still at the level before the last major market rally, indicating a high cost-performance ratio for investment [16]